Analysis of the Efficacy and Safety of Recombinant Tissue Plasminogen Activator for Chinese Patients over 80 Years of Age with Acute Ischemic Stroke: A Pilot Study.
作者信息
Yang Jiandao, Liang Huazheng, Song Yanyan, Shen Lingda, Wang Shaoshi
机构信息
Department of Neurology, North Sichuan Road Branch of Shanghai First People's Hospital, Shanghai, 200081, China.
Neuroscience Research Australia, Randwick, NSW, 2031, Australia.
出版信息
Neurosci Bull. 2016 Apr;32(2):202-3. doi: 10.1007/s12264-016-0020-2. Epub 2016 Mar 9.
Abstract
摘要
相似文献
1
Analysis of the Efficacy and Safety of Recombinant Tissue Plasminogen Activator for Chinese Patients over 80 Years of Age with Acute Ischemic Stroke: A Pilot Study.重组组织型纤溶酶原激活剂治疗80岁以上中国急性缺血性脑卒中患者的疗效和安全性分析：一项前瞻性研究
Neurosci Bull. 2016 Apr;32(2):202-3. doi: 10.1007/s12264-016-0020-2. Epub 2016 Mar 9.
2
Combined lysis of thrombus with ultrasound and systemic tissue plasminogen activator for emergent revascularization in acute ischemic stroke (CLOTBUST-ER): design and methodology of a multinational phase 3 trial.超声联合全身组织纤溶酶原激活剂溶解血栓用于急性缺血性卒中紧急血管再通（CLOTBUST-ER）：一项跨国3期试验的设计与方法
Int J Stroke. 2015 Oct;10(7):1141-8. doi: 10.1111/ijs.12536. Epub 2015 Jun 29.
3
Tenecteplase for acute ischemic stroke.替奈普酶用于急性缺血性卒中
Int J Stroke. 2011 Dec;6(6):509-10. doi: 10.1111/j.1747-4949.2011.00695.x.
4
Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke Patients Receiving Thrombectomy: Standard or Low Dose Therapy?接受血栓切除术的急性缺血性中风患者使用重组组织型纤溶酶原激活剂：标准剂量还是低剂量疗法？
Curr Neurovasc Res. 2018;15(3):204-210. doi: 10.2174/1567202615666180717113526.
5
[Intravenous thrombolysis in the treatment of acute ischaemic stroke: 3, 4.5, or 6 hours?].[静脉溶栓治疗急性缺血性卒中：3小时、4.5小时还是6小时？]
Neurol Neurochir Pol. 2009 May-Jun;43(3):213-5.
6
Different doses of recombinant tissue-type plasminogen activator for acute stroke in Chinese patients.不同剂量重组组织型纤溶酶原激活剂治疗中国急性脑卒中患者的疗效。
Stroke. 2014 Aug;45(8):2359-65. doi: 10.1161/STROKEAHA.114.005245. Epub 2014 Jul 3.
7
Intravenous thrombolysis for acute ischemic stroke in the 3- to 4·5-hour window--the Malabar experience.3至4.5小时时间窗内急性缺血性卒中的静脉溶栓治疗——马拉巴尔地区的经验
Int J Stroke. 2014 Jun;9(4):426-8. doi: 10.1111/ijs.12128. Epub 2013 Aug 26.
8
Review of tissue plasminogen activator, ischemic stroke, and potential legal issues.组织型纤溶酶原激活剂、缺血性中风及潜在法律问题综述
Arch Neurol. 2008 Nov;65(11):1429-33. doi: 10.1001/archneur.65.11.1429.
9
Tissue plasminogen activator use in a patient with acute ischemic stroke coexisting with meningioma.组织型纤溶酶原激活剂在一名合并脑膜瘤的急性缺血性脑卒中患者中的应用。
Clin Neurol Neurosurg. 2009 Jul;111(6):562-3. doi: 10.1016/j.clineuro.2009.01.004. Epub 2009 Feb 6.
10
Treating the elderly stroke patient: complications, controversies, and best care metrics.治疗老年中风患者：并发症、争议和最佳护理指标。
Clin Geriatr Med. 2013 Feb;29(1):231-55. doi: 10.1016/j.cger.2012.10.001.
引用本文的文献
1
Characteristics, temporal trends and outcomes of intravenous thrombolysis in Chinese patients aged>80 years who had a stroke.80岁以上中国脑卒中患者静脉溶栓治疗的特点、时间趋势及预后
Stroke Vasc Neurol. 2025 Aug 26;10(4):431-440. doi: 10.1136/svn-2024-003427.
2
Blockade of HCN2 Channels Provides Neuroprotection Against Ischemic Injury via Accelerating Autophagic Degradation in Hippocampal Neurons.阻断 HCN2 通道通过加速海马神经元自噬降解提供对缺血性损伤的神经保护。
Neurosci Bull. 2020 Aug;36(8):875-894. doi: 10.1007/s12264-020-00513-7. Epub 2020 Jun 10.
3
Neuroprotective Autophagic Flux Induced by Hyperbaric Oxygen Preconditioning is Mediated by Cystatin C.高压氧预处理诱导的神经保护自噬流是由胱抑素 C 介导的。
Neurosci Bull. 2019 Apr;35(2):336-346. doi: 10.1007/s12264-018-0313-8. Epub 2018 Dec 5.
4
The Possibility and Molecular Mechanisms of Cell Pyroptosis After Cerebral Ischemia.脑缺血后细胞焦亡的可能性及分子机制
Neurosci Bull. 2018 Dec;34(6):1131-1136. doi: 10.1007/s12264-018-0294-7. Epub 2018 Oct 10.
本文引用的文献
1
Third International Stroke Trial 3: an update.第三次国际卒中试验 3：更新。
Curr Opin Neurol. 2014 Feb;27(1):8-12. doi: 10.1097/WCO.0000000000000045.
2
Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.急性缺血性脑卒中患者早期管理指南：美国心脏协会/美国卒中协会医疗保健专业人员指南。
Stroke. 2013 Mar;44(3):870-947. doi: 10.1161/STR.0b013e318284056a. Epub 2013 Jan 31.
3
Intravenous thrombolysis in acute ischaemic stroke: a systematic review and meta-analysis to aid decision making in patients over 80 years of age.静脉溶栓治疗急性缺血性脑卒中：一项系统评价和荟萃分析，以帮助 80 岁以上患者做出决策。
J Neurol Neurosurg Psychiatry. 2011 Jul;82(7):712-7. doi: 10.1136/jnnp.2010.223149. Epub 2011 Feb 3.
4
Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITS-ISTR.阿替普酶溶栓治疗急性脑卒中后 3-4.5 小时的实施和结果：来自 SITS-ISTR 的最新分析。
Lancet Neurol. 2010 Sep;9(9):866-74. doi: 10.1016/S1474-4422(10)70165-4. Epub 2010 Jul 26.
5
Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials.静脉注射重组组织型纤溶酶原激活剂治疗时间与卒中转归：ECASS、ATLANTIS、NINDS 和 EPITHET 试验的更新汇总分析。
Lancet. 2010 May 15;375(9727):1695-703. doi: 10.1016/S0140-6736(10)60491-6.
6
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.急性缺血性卒中发病3至4.5小时后使用阿替普酶进行溶栓治疗。
N Engl J Med. 2008 Sep 25;359(13):1317-29. doi: 10.1056/NEJMoa0804656.
7
Burden of first-ever ischemic stroke in the oldest old: evidence from a population-based study.高龄老人首次缺血性卒中负担：一项基于人群研究的证据
Neurology. 2004 Jan 13;62(1):77-81. doi: 10.1212/01.wnl.0000101461.61501.65.
8
Stroke incidence and case fatality in Australasia. A comparison of the Auckland and Perth population-based stroke registers.澳大拉西亚地区的中风发病率和病死率。奥克兰和珀斯基于人群的中风登记数据比较。
Stroke. 1994 Mar;25(3):552-7. doi: 10.1161/01.str.25.3.552.
Zotero 插件